secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2024-01-02T23:59:59+00:00
Accession:  0001193125-24-000247
Event type: litigation
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Court finds Teva does not infringe Corcept's Korlym patents; Corcept plans appeal
--------------------------------------------------------------------------------

- District of New Jersey ruled Teva does not infringe Corcept's U.S. Patents 10,195,214 and 10,842,800.
- Patents cover methods of safely administering Korlym with strong CYP3A4 inhibitors.
- CEO Joseph Belanoff called decision disappointing and based on legal and factual errors.
- Corcept will pursue a vigorous appeal; believes patents expanded treatment options for Cushing's syndrome.
- FDA had added the patented methods to Korlym's prescribing instructions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000119312524000247/0001193125-24-000247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000119312524000247/d676865d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-000247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer